Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma

References

• Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;12: 920–932.
   Web of Science ®Google Scholar
• Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014;8:517–534.
   Web of Science ®Google Scholar
• Khaled AR, Durum SK. Lymphocide: cytokines and the control of lymphoid homeostasis. Nat Rev Immunol 2002;11:817–830.
   Web of Science ®Google Scholar
• Cohen S, Shachar I. Cytokines as regulators of proliferation and survival of healthy and malignant peripheral B cells. Cytokine 2012;1:13–22.
   Web of Science ®Google Scholar
• Hsu SM, Waldron JW, Hsu PL, Hough a J. Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol 1993;10:1040–1057.
   Web of Science ®Google Scholar
• Moens L, Tangye SG. Cytokine-mediated regulation of plasma cell generation:IL-21 takes center stage. Front Immunol 2014;5:65.
   PubMed Web of Science ®Google Scholar
• Woodland RT, Schmidt MR. Homeostatic proliferation of B cells. Semin Immunol 2005;3:209–217.
   Web of Science ®Google Scholar
• Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;5: 1851–1861.
   Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;22:2313–2323.
   Web of Science ®Google Scholar
• Jin P, Panelli MC, Marincola FM, et al. Cytokine polymorphism and its possible impact on cancer. Immunol Res 2004;2:181–190.
   Web of Science ®Google Scholar
• Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;9046:170–173.
   Web of Science ®Google Scholar
• Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005;19:1466–1474.
   Web of Science ®Google Scholar
• Chang CQ, Yesupriya A, Rowell JL, et al. A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes. Eur J Hum Genet 2014;3:402–408.
   Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;10:749–759.
   Web of Science ®Google Scholar
• Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997;2: 149–153.
   Web of Science ®Google Scholar
• Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999;66:562–566.
   PubMed Web of Science ®Google Scholar
• Abdou a M, Gao X, Cozen W, et al. Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma. Leukemia 2010;5:1055–1058.
   Web of Science ®Google Scholar
• Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;1:27–38.
   Web of Science ®Google Scholar
• Thunberg U, Enblad G, Turesson I, et al. Genetic variation in tumor necrosis factor and risk of diffuse large B-cell lymphoma and follicular lymphoma: differences between subgroups in Swedish patients. Leuk. Lymphoma 2010;8:1563–1566.
   Web of Science ®Google Scholar
• Yri OE, Ekstrøm PO, Hilden V, et al. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk Lymphoma 2013;10:2205–2214.
   Web of Science ®Google Scholar
• Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998;10:3574–3581.
   Google Scholar
• Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002;8:3037–3040.
   Web of Science ®Google Scholar
• Nasiri H, Farajnia S, Rezamand A, et al. Genetic variations of tumor necrosis factor -α-308 and lymphtoxin-α+ 252 in non-hodgkin lymphoma and acute lymphoblastic leukemia patients. Iran J Basic Med Sci 2013;9:990–995.
   Google Scholar
• Wang SS, Cozen W, Cerhan JR, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007;10:5042–5054.
   Web of Science ®Google Scholar
• Cerhan JR, Liu-Mares W, Fredericksen ZS, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008;11:3161–3169.
   Web of Science ®Google Scholar
• Nieters A, Conde L, Slager SL, et al. PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma:results from the InterLymph consortium. Blood 2012;23:4645–4648.
   Web of Science ®Google Scholar
• Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006;19:9771–9780.
   Web of Science ®Google Scholar
• Cao C, Liu S, Lou S-F, Liu T. The + 252A/G polymorphism in the Lymphotoxin-α gene and the risk of non-Hodgkin lymphoma: a meta-analysis. Eur Rev Med Pharmacol Sci 2014;4:544–552.
   Google Scholar
• Skibola CF, Nieters A, Bracci PM, et al. A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 2008;8: 4348–4354.
   Web of Science ®Google Scholar
• Wang SS, Purdue MP, Cerhan JR, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009;4:e5360.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;2:530–541.
   Web of Science ®Google Scholar
• Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 2013;S1.
   Google Scholar
• Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010;3:267–276.
   Web of Science ®Google Scholar
• Cunningham LM, Chapman C, Dunstan R, et al. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk. Lymphoma 2003;2: 251–255.
   Web of Science ®Google Scholar
• Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;10:4101–4108.
   Web of Science ®Google Scholar
• Lech-Maranda E, Baseggio L, Charlot C, et al. Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 2007;11:2235–2238.
   Web of Science ®Google Scholar
• Nieters A, Beckmann L, Deeg E, et al. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006;8:615–624.
   Web of Science ®Google Scholar
• Bogunia-Kubik K, Mazur G, Wróbel T, et al. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008;2:146–150.
   Web of Science ®Google Scholar
• Cao H-Y, Zou P, Zhou H. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. Gene 2013;2:288–294.
   Web of Science ®Google Scholar
• Mazur G, Bogunia-Kubik K, Wróbel T, et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 2005;2:241–246.
   Web of Science ®Google Scholar
• Pedersen LM, Klausen TW, Davidsen UH, et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005;8:510–516.
   Web of Science ®Google Scholar
• Li J, Mai J. Polymorphism in interleukin 21 gene is associated with decreased susceptibility to diffuse large B cell lymphoma. Tumour Biol 2014;35:11295–11300.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang M, Feng Z, et al. Functional interleukin-21 polymorphism is a protective factor of diffuse large B-cell lymphoma. DNA Cell Biol 2014;11:775–780.
   Web of Science ®Google Scholar
• Lan Q, Wang SS, Menashe I, et al. Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma:a pooled analysis of three population-based case-control studies. Br J Haematol 2011;3:341–350.
   Web of Science ®Google Scholar
• Cozen W, Gill PS, Salam MT, et al. Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood 2008;7:3377–3382.
   Web of Science ®Google Scholar
• Song H, Chen L, Cha Z, Bai J. Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma. DNA Cell Biol 2012;7:1279–1284.
   Web of Science ®Google Scholar
• Rutkowski MJ, Sughrue ME, Kane AJ, et al. Cancer and the complement cascade. Mol. Cancer Res 2010;11:1453–1465.
   Web of Science ®Google Scholar
• Bassig BA, Zheng T, Zhang Y, et al. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2012;2:145–151.
   Web of Science ®Google Scholar
• Hu W, Bassig BA, Xu J, et al. Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2013;1:72–77.
   Web of Science ®Google Scholar
• Cerhan JR, Novak AJ, Fredericksen ZS, et al. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. 2009;145:614–623.
   Google Scholar
• Mayilyan KR. Complement genetics, deficiencies, and disease associations. Protein Cell 2012;7:487–496.
   Web of Science ®Google Scholar
• Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007;13:4455–4463.
   Web of Science ®Google Scholar
• Purdue MP, Lan Q, Kricker A, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma:findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007;3:704–712.
   Google Scholar
• Chen K, Huang J, Gong W, et al. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007;10:1271–1285.
   Web of Science ®Google Scholar
• Tantisira K, Klimecki WT, Lazarus R, et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004;5:343–346.
   PubMed Web of Science ®Google Scholar
• Stevens VL, Hsing AW, Talbot JT, et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer 2008;11:2644–2650.
   Web of Science ®Google Scholar
• Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006;2:180–183.
   Web of Science ®Google Scholar
• Van der Linde K, Boor PPC, Houwing-Duistermaat JJ, et al. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies. Eur J Gastroenterol Hepatol 2007;6:449–459.
   Web of Science ®Google Scholar
• Carvalho A, Cunha C, Almeida AJ, et al. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun 2012;2:197–201.
   Web of Science ®Google Scholar
• Thiel S, Kolev M, Degn S, et al. Polymorphisms in mannan-binding lectin (MBL)-associated serine protease 2 affect stability, binding to MBL, and enzymatic activity. J Immunol 2009;5:2939–2947.
   Web of Science ®Google Scholar
• Giltiay N V, Chappell CP, Clark EA. B-cell selection and the development of autoantibodies. Arthritis Res Ther 2012;S1.
   Google Scholar
• Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk. Lymphoma 2004;12:2491–2496.
   Web of Science ®Google Scholar
• Bracci PM, Skibola CF, Conde L, et al. Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma 2010;3:497–506.
   Web of Science ®Google Scholar
• Song H, Tong D, Cha Z, Bai J. C-X-C chemokine receptor type 5 gene polymorphisms are associated with non-Hodgkin lymphoma. Mol Biol Rep 2012;9:8629–8635.
   Web of Science ®Google Scholar
• Charbonneau B, Wang AH, Maurer MJ, et al. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol. Immunother 2013;9:1475–1484.
   Web of Science ®Google Scholar
• Ding BB, Yu JJ, Yu RY-L, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;3:1515–1523.
   Google Scholar
• Butterbach K, Beckmann L, de Sanjosé S, et al. Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph). Br J Haematol 2011;3:318–333.
   Web of Science ®Google Scholar
• Heredia-Galvez B, Ruiz-Cosano J, Torres-Moreno D, et al. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Ann Hematol 2014;2:243–247.
   Web of Science ®Google Scholar
• Cerhan JR, Fredericksen ZS, Novak AJ, et al. A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region. Cancer Epidemiol Biomarkers Prev 2012;21:1799–1806.
   PubMed Web of Science ®Google Scholar
• Conde L, Halperin E, Akers NK, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010;8:661–664.
   Web of Science ®Google Scholar
• Smedby KE, Foo JN, Skibola CF, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011;4:e1001378.
   Web of Science ®Google Scholar
• Skibola CF, Conde L, Foo J-N, et al. A meta-analysis of genome-wide association studies of follicular lymphoma. BMC Genomics 2012;516.
   Google Scholar
• Vijai J, Kirchhoff T, Schrader KA, et al. Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet 2013;1:e1003220.
   Web of Science ®Google Scholar
• Skibola CF, Berndt SI, Vijai J, et al. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am J Hum Genet 2014;4:462–71.
   Web of Science ®Google Scholar
• Qiao Y, Zhou Y, Wu C, et al. Risk of genome-wide association study-identified genetic variants for non-Hodgkin lymphoma in a Chinese population. Carcinogenesis 2013;34:1516–1519.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Berndt SI, Vijai J, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 2014;11:1233–1238.
   Web of Science ®Google Scholar
• Thorsby E. Invited anniversary review: HLA associated diseases. Hum Immunol 1997;1:1–11.
   Web of Science ®Google Scholar
• Fitzgibbon J, Grenzelias D, Matthews J, et al. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol 1999;2:388–391.
   Web of Science ®Google Scholar
• Spink CF, Keen LJ, Mensah FK, et al. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol 2006;3:293–300.
   Web of Science ®Google Scholar
• Green MR, Vicente-Dueñas C, Alizadeh AA, et al. Hit-and- run lymphomagenesis by the Bcl6 oncogene. Cell Cycle 2014;12: 1831–1832.
   Web of Science ®Google Scholar
• Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Prognostic biomarkers in malignant lymphomas. Leuk Lymphoma 2010;51:11–19.
   Web of Science ®Google Scholar
• Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, et al. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz). 2010;2:131–141.
   Web of Science ®Google Scholar
• El-Galaly TC, Bilgrau AE, Gaarsdal E, et al. Circulating TNF α and YKL-40 level is associated to remission status following salvage therapy in relapsed non-Hodgkin lymphoma. Leuk Lymphoma 2015;24:1–3.
   Web of Science ®Google Scholar
• Tarabar O, Cikota-Aleksić B, Tukić L, et al. Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas. Int J Clin Oncol 2013;19:186–192.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Wang SS, Maurer MJ, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008;7:2694–2702.
   Web of Science ®Google Scholar
• Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004;9:3529–3534.
   Web of Science ®Google Scholar
• Kube D, Hua T-D, von Bonin F, et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma:an exploratory study. Clin Cancer Res 2008;12:3777–3784.
   Web of Science ®Google Scholar
• Aschebrook-Kilfoy B, Zheng T, Foss F, et al. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv 2012;1:102–114.
   Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Di Febo A, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007;8:1376–1381.
   Web of Science ®Google Scholar
• Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012;3:411–416.
   Web of Science ®Google Scholar
• Kay NE, Pittner BT. IL-4 biology:impact on normal and leukemic CLL B cells. Leuk Lymphoma 2003;6:897–903.
   Web of Science ®Google Scholar
• Schoof N, von Bonin F, Zeynalova S, et al. Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol 2009;9:1548–1554.
   Web of Science ®Google Scholar
• Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Cli. Ann Oncol 2005;10:1675–1682.
   Web of Science ®Google Scholar
• Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940–3947.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;3:754–758.
   Web of Science ®Google Scholar
• Warmerdam PA, van de Winkel JG, Vlug A, et al. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991;4:1338–1343.
   Google Scholar
• Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;3:1109–1114.
   Google Scholar
• Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;5:1059–1070.
   Web of Science ®Google Scholar
• Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007;8:1127–1130.
   Web of Science ®Google Scholar
• Pennell NM, Bhanji T, Zhang L, et al. Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma. Haematologica 2008;8:1265–1267.
   Web of Science ®Google Scholar
• Liu F, Ding H, Jin X, et al. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 2014;9:616–623.
   Web of Science ®Google Scholar
• Lu Y, Abdou AM, Cerhan JR, et al. Human leukocyte antigen class I and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Scientific World J 2011;2062–2070.
   Web of Science ®Google Scholar
• Alcoceba M, Sebastián E, Marín L, et al. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood 2013;8:1448–1454.
   Web of Science ®Google Scholar
• Gibson TM, Wang SS, Cerhan JR, et al. Inherited genetic variation and overall survival following follicular lymphoma. Am J Hematol 2012;724–726.
   PubMed Web of Science ®Google Scholar
• Baecklund F, Foo J-N, Bracci P, et al. A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. BMC Med Genet 2014;1:113.
   Web of Science ®Google Scholar
• Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;10:2440–2452.
   Web of Science ®Google Scholar
• Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009;6:392–404.
   Web of Science ®Google Scholar
• Steen K Van. Travelling the world of gene-gene interactions. Brief Bioinform 2012;1:1–19.
   Web of Science ®Google Scholar
• Monroy CM, Cortes AC, Lopez MS, et al. Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 2011;1:36–46.
   Web of Science ®Google Scholar
• Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;12:5439–5446.
   Web of Science ®Google Scholar
• Amos W, Driscoll E, Hoffman JI. Candidate genes versus genome-wide associations: which are better for detecting genetic susceptibility to infectious disease? Proc Biol Sci 2011;1709:1183–1188.
   Web of Science ®Google Scholar
• Guenther CA, Tasic B, Luo L, et al. A molecular basis for classic blond hair color in Europeans. Nat Genet 2014;7:748–752.
   Web of Science ®Google Scholar
• Dc W, Blay BJ, Burdin N, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. 2014;2169–2174.
   Google Scholar
• De Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011;2:135–146.
   Web of Science ®Google Scholar
• Juszczynski P, Kalinka E, Bienvenu J, et al. Brief report: Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002;100:3037–3040.
   PubMed Web of Science ®Google Scholar
• Lim Y-Y, Chin Y-M, Tai M-C, et al. Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population. Leuk Lymphoma 2015;56: 163–168.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Slager SL, Fredericksen ZS, et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009;10:4217–4224.
   Web of Science ®Google Scholar
• Matsuo K, Hamajima N, Suzuki R, et al. No substantial difference in genotype frequencies of interleukin and myeloperoxidase polymorphisms between malignant lymphoma patients and non-cancer controls. Haematologica 2001;6:602–608.
   Google Scholar
• Nieters A, Bracci PM, de Sanjosé S, et al. A functional TNFRSF5 polymorphism and risk of non-Hodgkin lymphoma, a pooled analysis. Int J Cancer 2011;6:1481–1485.
   Web of Science ®Google Scholar
• Hildebrand JM, Luo Z, Manske MK, et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med 2010;12: 2569–2579.
   Web of Science ®Google Scholar
• Purdue MP, Lan Q, Wang SS, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009;2:275–281.
   Google Scholar
• Hosgood HD, Purdue MP, Wang SS, et al. A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk. Br J Haematol 2011;6:721–726.
   Web of Science ®Google Scholar
• Morton LM, Purdue MP, Zheng T, et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009;4:1259–1270.
   Web of Science ®Google Scholar
• Nieters A, Conde L, Slager SL, et al. PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma:results from the InterLymph consortium. Blood 2012;23:4645–4648.
   Web of Science ®Google Scholar
• Schuetz JM, Daley D, Leach S, et al. Polymorphisms in integrin genes and lymphoma risk. PLoS One 2013;9:e75170.
   Web of Science ®Google Scholar
• Shen M, Zheng T, Lan Q, et al. Non-Hodgkin lymphoma risk and variants in genes controlling lymphocyte development. Leuk Res 2011;35:968–970.
   PubMed Web of Science ®Google Scholar
• Slager SL, Achenbach SJ, Asmann YW, et al. Mapping of the IRF8 gene identifies a 3’UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes. Cancer Epidemiol Biomarkers Prev 2013;3:461–466.
   Web of Science ®Google Scholar
• Slager SL, Camp NJ, Conde L, et al. Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. Br J Haematol 2012;5:572–576.
   Google Scholar
• Akers NK, Curry JD, Conde L, et al. Association of HLA-DQB1 alleles with risk of follicular lymphoma. Leuk Lymphoma 2011;1:53–58.
   Web of Science ®Google Scholar
• Kumar V, Matsuo K, Takahashi A, et al. Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility. J Hum Genet 2011;6:436–439.
   Web of Science ®Google Scholar
• Gustafson HL, Yao S, Goldman BH, et al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. Am J Hematol 2014;6:639–645.
   Web of Science ®Google Scholar
• Chae YS, Kim JG, Sohn SK, et al. Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. Cancer Chemother Pharmacol 2010;3:571–577.
   Web of Science ®Google Scholar
• Charbonneau B, Maurer MJ, Fredericksen ZS, et al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol 2012;9:880–885.
   Web of Science ®Google Scholar
• Weng W-K, Czerwinski D, Timmerman J, et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004;23:4717–4724.
   Web of Science ®Google Scholar
• Levy D, Bellesso M, Oliveira-Souza P, et al. The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population. Clinics 2011;5:919–922.
   Web of Science ®Google Scholar
• Lu Y, Abdou AM, Cerhan JR, et al. Human leukocyte antigen class I and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Scientific World J 2011;2062–2070.
   Web of Science ®Google Scholar